Asensus Surgical Inc

Asensus Surgical — SafeStitch Medical — Q3 2013 Earnings Presentation

23 slides from Asensus Surgical's earnings presentation, Nov 18, 2013

  1. Slide 1: Advancing Surgery Through Innovation

    Slide 1: Advancing Surgery Through Innovation

    Advancing Surgery Through Innovation Exhibit 99.3

  2. Slide 2: Cautionary Statement

    Slide 2: Cautionary Statement

    Cautionary Statement 2 Any statements contained in this presentation that do not describe historical facts, including statements about the beliefs and expectations of SafeStitch Medical, Inc. (“SafeStitch”) and TransEnterix, Inc. (“TransEnterix”), may constitute forward-looking statements as that te

  3. Slide 3: Financial Overview

    Slide 3: Financial Overview

    3 Financial Overview Joe Slattery Executive Vice President & CFO

  4. Slide 4: Advancing Surgery Through Innovation

    Slide 4: Advancing Surgery Through Innovation

    Advancing Surgery Through Innovation

  5. Slide 5: Investment Highlights

    Slide 5: Investment Highlights

    Investment Highlights Focus Technology Solution Market Team • Surgical robotics • Developing patient-side robotic platform: SurgiBot • Addresses unmet needs in today’s robotic offerings • Large addressable market – ~2M US procedures • Strong management team • Cost effective • Broad procedure applica

  6. Slide 6: Company History

    Slide 6: Company History

    Company History 6 2006 2009 2010 2012 2013 • TransEnterix founded • FDA 510(K) clearance for Spider Surgical System • CE Mark clearance and release of Spider Surgical System • >3,000 SPIDER cumulative procedures performed to date • Began SurgiBot development • SurgiBot preclinical labs • Merger with

  7. Slide 7: Merger with SafeStitch Medical

    Slide 7: Merger with SafeStitch Medical

    Merger with SafeStitch Medical 7 • Transaction closed on September 4, 2013 • About SafeStitch – Publicly-traded, development stage medical device company (OTCBB: SFES) – Obesity and GERD-focused, flexible endoluminal instrumentation • Board and investors with demonstrated success in leading high-gro

  8. Slide 8: Surgical Progress = Less Invasive

    Slide 8: Surgical Progress = Less Invasive

    Surgical Progress = Less Invasive 8 Open Surgery Rigid Laparoscopy (1989) Flexible Laparoscopy (2010)

  9. Slide 9: Spider Surgical System Enabling Flexible Laparoscopy

    Slide 9: Spider Surgical System Enabling Flexible Laparoscopy

    Spider Surgical System Enabling Flexible Laparoscopy 9 • • • • • • Internal (intra-abdominal) triangulation Flexible, articulating instruments for dissection and retraction True left/right instrumentation Lower profile port of access Over 3,000 procedures performed Broad procedural mix

  10. Slide 10: Innovative, Minimally Invasive Robotic Platform SurgiBot

    Slide 10: Innovative, Minimally Invasive Robotic Platform SurgiBot

    Innovative, Minimally Invasive Robotic Platform SurgiBot TM

  11. Slide 11: Benefits of Surgical Robotics

    Slide 11: Benefits of Surgical Robotics

    Benefits of Surgical Robotics 11 Benefits of Surgical Robotics Improved dissection and retraction strength Enhanced precision and control Improved surgeon ergonomics Advanced visualization

  12. Slide 12: SurgiBot First Patient-side Robotic Platform

    Slide 12: SurgiBot First Patient-side Robotic Platform

    Confidential 12 SurgiBot First Patient-side Robotic Platform Positioning Arm Cart Endodrive Flex Instruments 3DHD Optics

  13. Slide 13: SurgiBot First Patient-side Robotic Platform

    Slide 13: SurgiBot First Patient-side Robotic Platform

    SurgiBot First Patient-side Robotic Platform 13 Surgeon scrubbed-in Flexible, articulating channels & instruments Flexible & steerable 3DHD Small, mobile platform Easily repositioned for multi- quadrant surgery Cost effective platform

  14. Slide 14: Benefits to Key Stakeholders

    Slide 14: Benefits to Key Stakeholders

    14 Benefits to Key Stakeholders Surgeons • Precision of robotic surgery • Advanced 3D visualization • Scrubbed-in patient-side • Ergonomics/reduced fatigue Hospitals and Surgical Centers • Attractive ROI for many health care facilities, relative to competing robotic platforms • Strategic asset for s

  15. Slide 15: Large Addressable Market

    Slide 15: Large Addressable Market

    Large Addressable Market 15 1,566 2,054 930 458 Additionally over surgery centers in US 5,000 Source: CDC Over 5,000 Hospitals in the United States # of Beds Under 50 50-200 200-400 Over 400

  16. Slide 16: Hospital Market Opportunity

    Slide 16: Hospital Market Opportunity

    Hospital Market Opportunity Confidential 16 Hospitals without Robotic Capability Hospitals with Robotic Capability • Current robotic offerings are not cost effective • Price • Procedure volume • Surgery centers – untapped market for robotics • Large underpenetrated OUS opportunity • Invested in the

  17. Slide 17: Procedure Market Opportunity

    Slide 17: Procedure Market Opportunity

    17 Bariatric Surgery Cholecystectomy Colorectal Gynecology/Urology Procedure Market Opportunity Targeted US Procedures 160K 1,140K 363K 230K Source: Millennium Research Group US Markets Laparoscopic Devices 2014 Note: Company Estimate of Outside US addressable market = US opportunity ~2M US Laparosc

  18. Slide 18: Recurring Revenue Model

    Slide 18: Recurring Revenue Model

    Recurring Revenue Model 18 Capital Equipment Service Instruments and Accessories

  19. Slide 19: Commercial Pathway

    Slide 19: Commercial Pathway

    Commercial Pathway 19 2013 2014 2015 • Design & Pre-clinical Testing • Pre-submission FDA Meeting • First Human Procedures • Regulatory Submissions • Regulatory Clearances • Global Launch

  20. Slide 20: Management Team

    Slide 20: Management Team

    Management Team 20 Prior Experience Todd M. Pope President and Chief Executive Officer Joe Slattery EVP and Chief Financial Officer Richard Mueller Chief Operating Officer Mohan Nathan Vice President of Global Marketing Tammy Carrea Vice President, Quality and Regulatory Affairs

  21. Slide 21: Board of Directors and Healthcare Investors

    Slide 21: Board of Directors and Healthcare Investors

    21 Board of Directors Healthcare Investors Board of Directors and Healthcare Investors • Phillip Frost, M.D. – CEO and Chairman of OPKO Health – Chairman of Teva Pharmaceuticals • Jane Hsiao, Ph.D., MBA – Former Chairman of SafeStitch – Vice Chairman and CTO of OPKO Health • Aftab Kherani, M.D. – Pr

  22. Slide 22: Investment Highlights

    Slide 22: Investment Highlights

    Investment Highlights 22 Focus Technology Solution Market Team • Surgical robotics • Developing patient-side robotic platform: SurgiBot • Addresses unmet needs in today’s robotic offerings • Large addressable market – ~2M US procedures • Strong management team • Cost effective • Broad procedure appl

  23. Slide 23: Advancing Surgery Through Innovation

    Slide 23: Advancing Surgery Through Innovation

    Advancing Surgery Through Innovation

Source: SEC EDGAR · 8-K filed Nov 18, 2013

More decks from Asensus Surgical Inc